Lyra Therapeutics, Inc. — Director's Dealing 2020

May 1, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyra Therapeutics, Inc. (LYRA)
CIK: 0001327273
Period of Report: 2020-04-30

Reporting Person: Roberts Carmichael (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	57999	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1/A Convertible Preferred Stock	$		Common Stock (415)		Direct

Footnotes

F1: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock shall be automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering.